Literature DB >> 10524690

The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis.

B Harrison1, W Thomson, D Symmons, B Ollier, N Wiles, T Payton, E Barrett, A Silman.   

Abstract

OBJECTIVE: There are conflicting data concerning the role of HLA-DRB1 alleles in disease outcome in early rheumatoid arthritis. The exact role of these alleles in short-term outcome is determined in this large, prospective, population-based study.
METHODS: We recruited 532 patients with inflammatory polyarthritis from the Norfolk Arthritis Register and typed their sera for HLA-DRB1 alleles using polymerase chain reaction-based methods. Disease outcome was assessed at 2 years in terms of persistent joint inflammation, functional disability, and radiologic erosions. Results are expressed as risk ratios (RR) with 95% confidence intervals (95% CI).
RESULTS: There was no influence of HLA-DRB1 alleles, in any combination, on the likelihood of disease persistence, and only a modest effect on functional disability (Health Assessment Questionnaire score > or = 1). The most obvious effect was on the development of erosions (RR 1.9, 95% CI 1.4-2.6 for those who carried at least 1 DRB1 shared epitope [SE] allele), with slightly greater effects for those who were homozygous for SE-bearing alleles (RR 2.5, 95% CI 1.8-3.6). This effect of HLA-DRB1 was restricted to patients whose sera were negative for rheumatoid factor. Among patients with erosions, HLA-DRB1 had no influence on the severity of radiologic damage (defined as the number of eroded joints, or total Larsen score).
CONCLUSION: These data do not support routine HLA-DRB1 screening of patients with early arthritis to identify those at risk for subsequent severe disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10524690     DOI: 10.1002/1529-0131(199910)42:10<2174::AID-ANR19>3.0.CO;2-G

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

1.  Clinical, laboratory and genetic markers associated with erosions and remission in patients with early inflammatory arthritis: a prospective cohort study.

Authors:  A Stockman; B D Tait; R Wolfe; C A Brand; M J Rowley; M D Varney; R Buchbinder; K D Muirden
Journal:  Rheumatol Int       Date:  2005-09-07       Impact factor: 2.631

2.  The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population.

Authors:  H Marotte; B Pallot-Prades; L Grange; J Tebib; P Gaudin; C Alexandre; J L Blond; M A Cazalis; B Mougin; P Miossec
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

3.  Polymorphisms of interleukin-31 are associated with anti-CCP levels in females with rheumatoid arthritis.

Authors:  Ji-In Yu; Young-Ran Park; Shin-Seok Lee; Soo-Cheon Chae
Journal:  J Genet       Date:  2014-12       Impact factor: 1.166

4.  The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases.

Authors:  Ct Chou; Ht Liao; Ch Chen; Ws Chen; Hp Wang; Ky Su
Journal:  Biomark Insights       Date:  2007-05-03

5.  Association of TBX21 polymorphisms in a Korean population with rheumatoid arthritis.

Authors:  Soo Cheon Chae; Seung Cheol Shim; Hun Taeg Chung
Journal:  Exp Mol Med       Date:  2009-01-31       Impact factor: 8.718

6.  Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis.

Authors:  Hiba Mahdi; Benjamin A Fisher; Henrik Källberg; Darren Plant; Vivianne Malmström; Johan Rönnelid; Peter Charles; Bo Ding; Lars Alfredsson; Leonid Padyukov; Deborah P M Symmons; Patrick J Venables; Lars Klareskog; Karin Lundberg
Journal:  Nat Genet       Date:  2009-11-08       Impact factor: 38.330

7.  One year outcome of undifferentiated polyarthritis.

Authors:  L M A Jansen; D van Schaardenburg; I E van der Horst-Bruinsma; B A C Dijkmans
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

8.  Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations.

Authors:  L De Rycke; I Peene; I E A Hoffman; E Kruithof; A Union; L Meheus; K Lebeer; B Wyns; C Vincent; H Mielants; L Boullart; G Serre; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

9.  Investigation of polymorphisms in the PADI4 gene in determining severity of inflammatory polyarthritis.

Authors:  A Barton; J Bowes; S Eyre; D Symmons; J Worthington; A Silman
Journal:  Ann Rheum Dis       Date:  2005-02-24       Impact factor: 19.103

Review 10.  The positive effect of pregnancy in rheumatoid arthritis and the use of medications for the management of rheumatoid arthritis during pregnancy.

Authors:  Uday Raj Sharma; Akhila Nediyedath Rathnakaran; B P Prudhvi Raj; Gayathry Padinjakkara; Akanksh Das; Surendra Vada; Manjunatha P Mudagal
Journal:  Inflammopharmacology       Date:  2021-04-12       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.